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Abstract Ischaemic preconditioning is associated with the ac-
tivation of prosurvival mechanisms. Here we demonstrate that
following a preconditioning protocol, the proapoptotic p53 is
inactivated possibly via phosphatidylinositol 3-kinase (PI3K)-
protein kinase B (Akt)-murine double minute 2 (Mdm2) phos-
phorylation. Our data show that in preconditioned hearts Mdm2
was signi¢cantly phosphorylated, and wortmannin (a PI3K in-
hibitor) abrogated this e¡ect (Western blotting). Also in precon-
ditioned hearts p53 was shown to be bound to phospho-Mdm2
(co-immunoprecipitation). Furthermore, pi¢thrin K (a p53 inhib-
itor), administered to isolated perfused hearts prior to ischae-
mia, signi¢cantly attenuated the infarction. In conclusion our
results suggest that p53 is implicated in ischaemia/reperfusion
injury and that preconditioning counterbalances this e¡ect via
PI3K-Akt-Mdm2 phosphorylation.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Ischaemic preconditioning is considered the most powerful
form of myocardial protection known to date [1]. Precondi-
tioning consists of short periods of sublethal ischaemia with
intermittent reperfusion prior to a sustained lethal ischaemic
insult. Although it has been shown that the ischaemic precon-
ditioning is manifested as a reduction in both necrotic and
apoptotic cell death [2], the molecular mechanisms responsible
for this protection are still under extensive research. Recent
data indicate a signi¢cant role for the phosphatidylinositol
3-kinase (PI3K)-protein kinase B (Akt) signalling pathway
in this protection. It has been demonstrated that Akt can
phosphorylate a multitude of substrates, which are implicated
in cell survival. Amongst them there is murine double minute
2 (Mdm2) [3], an oncogenic factor that, when activated, pro-
motes p53 degradation. To achieve this, phospho-Mdm2
forms complexes with p53, masking its transactivation do-
main, promoting its nuclear export and targeting it for ubiq-
uitination [4,5].
p53 is a tumour suppressor protein and transcription factor
present in a latent state in all cells and activated by various
stresses such as hypoxia, free radicals, DNA damage and UV
light [6]. It is well documented that, when activated, it induces
the transcription of death proteins such as bax, Peg3, Apaf1,
p53AIP1 and Fas [7,8]. However, new evidence suggests that
p53 may also have immediate proapoptotic e¡ects, indepen-
dent of gene transcription, through the activation of mito-
chondrial apoptotic pathways [9,10].
Ischaemia/reperfusion injury has been shown to be associ-
ated with p53 activation in di¡erent organs and tissues, in-
cluding the myocardium [11], and lower levels of p53 follow-
ing ischaemia/reperfusion injury in preconditioned hearts were
reported [12]. Furthermore, studies performed in mouse brain,
both in vitro and in vivo, have shown that p53 inhibition
prior to ischaemia is correlated with a reduction in neuronal
infarction [13] and ischaemic preconditioning of rat brain has
been associated with a reduction in p53 activation [14].
However, there are no data in the literature about the de-
gree of implication of p53 either in the infarction induced by
ischaemia/reperfusion injury or in the mechanism which may
be responsible for p53 reduction following preconditioning.
With the above in mind, we hypothesised that one of the
possible mechanisms by which ischaemic preconditioning re-
duces cell death may be due to the downregulation of p53 via
Mdm2 phosphorylation, possible via PI3K-Akt activation.
For measuring Mdm2 phosphorylation we used the anti-
body against Ser166, as this has been shown in the literature
to be the major phosphorylation site of Akt on Mdm2 [15,16].
Our results show that Mdm2 is signi¢cantly phosphorylated in
preconditioned hearts. Moreover, phosphorylated Mdm2 is
bound to p53 in these hearts, a phenomenon that can be
correlated with signi¢cant resistance against a further lethal
ischaemic insult. This assessment is further supported by evi-
dence that in preconditioned hearts the level of p53 during
reperfusion, after a lethal ischaemic insult, is signi¢cantly low-
er. Additional evidence for a role for p53 in ischaemia/reper-
fusion injury is demonstrated by the reduction in infarction
observed when pi¢thrin K, a p53 inhibitor [17], was adminis-
tered prior to the ischaemic insult or at reperfusion.
2. Materials and methods
2.1. Materials
Sprague^Dawley male rats (350^400 g) were used in all experi-
ments. Animal care was done in accordance with The Guidance on
the Operation of the Animals (Scienti¢c Procedure) Act 1986.
Antibodies against rat phospho-Mdm2 (Ser166) and total p53 were
purchased from Cell Signalling, antibodies against rat total Mdm2
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from Upstate Technology, G-agarose beads from Roche Diagnostics,
pi¢thrin K from Calbiochem and wortmannin (PI3K inhibitor) from
Tocris.
2.2. Western blotting and immunoprecipitation
Isolated rat hearts were retrogradely perfused via the aorta (Lan-
gendor¡ preparation) in a constant pressure system. They were ran-
domly divided into the following groups: group 1: perfused for 45
min (sham, n=5); group 2: sham hearts perfused for 45 min in the
presence of 100 nM wortmannin (n=3); group 3: hearts precondi-
tioned with two episodes of 5 min global normothermic ischaemia
each followed by 10 min reperfusion (n=5); group 4: hearts precon-
ditioned in the presence of 100 nM wortmannin (n=3); group 5:
control hearts undergoing 35 min lethal regional ischaemia by ob-
struction of the left coronary artery, followed by 15 min reperfusion
induced by reopening of the artery (n=3); group 6: preconditioned
hearts (as above, with two episodes of 5 min global normothermic
ischaemia each followed by 10 min reperfusion) which underwent 35
min regional ischaemia and 15 min reperfusion (n=5). At the end of
the experiments hearts were rapidly frozen in liquid nitrogen. Exper-
imental protocols are represented in Fig. 1A (for groups 1^4) and Fig.
3A (for groups 5 and 6). We used global ischaemia for inducing the
preconditioning protection and regional ischaemia for inducing the
lethal injury to avoid repeated mechanical obstructions of the coro-
nary artery, which could induce permanent damage of the artery and
therefore interfere with the infarction data. Wortmannin was used in a
dose previously reported to block Akt phosphorylation [18,19] in the
preconditioned hearts. The dose of pi¢thrin K was chosen in accor-
dance with literature and some preliminary data we obtained using a
range of concentrations (data not included) to ascertain heart function
and protection.
Western blotting analysis was performed to determine the level of
p53, phosphorylated Mdm2 and total Mdm2. Immunoprecipitation
was performed in order to investigate the presence of the p53^
Mdm2 complexes.
Frozen ventricular tissue (50 mg) was used for protein extraction.
We were interested to estimate the total content of phospho-Mdm2,
p53 and their association without investigating the time course of
their association and migration between cytosol and nuclear fraction;
therefore we used total tissue homogenate. Tissue was homogenised
on ice using a IKA Labortechnik T25 basic homogeniser in either (a)
250 Wl suspension bu¡er: (in mM) NaCl 100, Tris 10 (pH 7.6), EDTA
1 (pH 8), sodium pyrophosphate 2, sodium £uoride 2, L-glycerophos-
phate 2; Sigma protease inhibitor cocktail (Western blotting) or (b)
250 Wl Ripa bu¡er containing the protease inhibitor (immunoprecip-
itation). Samples were centrifuged at 10 000 rpm, 10 min at 4‡C on a
bench centrifuge, the supernatant was collected and protein concen-
trations were estimated using BCA protein assay reagent (Pierce).
For Western blotting the supernatant was further diluted in 1:1 in
sample bu¡er: (in mM) Tris 100 (pH 6.8), dithiothreitol 200, sodium
dodecyl sulfate (SDS) 2%, bromophenol blue 0.2% and glycerol 20%,
and subsequently boiled for 10 min at 100‡C. A total protein quantity
of 30 Wg for each sample was separated on a 12.5% SDS^polyacryl-
amide gel electrophoresis gel and transferred to Hybond ECL nitro-
cellulose membranes (Amersham). Equal protein loading was con-
¢rmed by Ponceau red staining (Sigma) of membranes. Blots were
probed with p53, Mdm2 or phospho-Mdm2 primary rabbit polyclonal
antibodies and subsequently probed with horseradish peroxidase-con-
jugated anti-rabbit antibody according to the supplier’s protocols.
Proteins were detected using enhanced chemiluminescence ECL West-
ern blotting detection reagent and bands were visualised by autora-
diography.
The samples for the immunoprecipitation assay (1000 Wg protein
each) were incubated with 5 Wl p53 antibody, on ice with shaking for
60 min, then 20 Wl G-agarose spheres were added and the samples
were further incubated on ice with shaking for 4 h. At the end of this
period the samples were centrifuged at 7000 rpm, 4‡C, 10 min, the
supernatant discharged, and the pellet resuspended in Ripa bu¡er and
recentrifuged. This last step was repeated four times. After the ¢nal
centrifugation 30 Wl of suspension bu¡er was added to the pellet and
samples were boiled for 10 min at 100‡C.
To rule out the possibility that the agarose beads may give unreli-
able results by binding to unspeci¢c phosphorylated proteins, parallel
protein extracts were incubated with agarose spheres in the absence of
p53 antibody.
All the protocols were repeated in triplicate starting with the tissue
homogenisation step.
2.3. Infarct data
2.3.1. Heart preparation. The animals were anaesthetised via an
i.p. administration of sodium pentobarbital (55 mg/kg) and heparin
(300 U). The hearts were excised, placed in ice-cold bu¡er and within
1 min mounted in a constant pressure Langendor¡ system (70 mm
Hg). They were retrogradely perfused with a modi¢ed Krebs^Hense-
leit bicarbonate bu¡er containing (in mM): NaCl 118.5, NaHCO3 25,
KCl 4.8, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.7 and glucose 12. All
solutions were gassed with 95% O2/5% CO2 (pH 7.4) and maintained
at 37‡C. The temperature was permanently monitored by a thermo-
couple inserted in the right ventricle. An isovolumic latex balloon was
introduced in the left ventricle through an insertion performed in the
left atrial appendage and in£ated to a diastolic pressure of 5^10 mm
Hg. Functional monitoring was performed via a pressure transducer
connected to an AD Instruments computerised system and recorded
continuously. To induce ischaemia a surgical needle was inserted
under the left main coronary artery and the ends of the thread were
passed through a small plastic tube to form a snare. Tightening the
snare induced regional ischaemia and releasing the ends of the thread
allowed reperfusion to commence. At the end of reperfusion, the snare
was tightened to re-occlude the coronary artery branch. A saline so-
lution of 0.12% Evans blue was infused slowly via the aorta to delin-
eate the non-ischaemic zone of the myocardium, which stained dark
blue. The hearts were frozen, sliced into 1 mm thick transverse sec-
tions and incubated in triphenyl-tetrazolium chloride solution (1% in
phosphate bu¡er, pH 7.4) at 37‡C for 10^12 min. They were then
¢xed in 10% formalin, for at least 4 h. Viable tissue stains red and
infarcted tissue appears pale. The risk zone and infarct areas were
traced onto acetate sheets. Using computerised planimetry (Summa
Sketch II, Summagraphics) the percentage of infarcted tissue within
the volume of the myocardium at risk was calculated (I/R%).
2.3.2. Groups. The hearts were randomly divided into four
groups: (a) controls which su¡er 35 min regional ischaemia and 120
min reperfusion (n=6), (b) preconditioned (n=6) with two times 5 min
global ischaemia interspaced with 10 min reperfusion prior to lethal
ischaemia, (c) control hearts treated with the p53 inhibitor pi¢thrin K
at 10 WM, for 15 min before ischaemia (n=8) and (d) control hearts
treated with the p53 inhibitor starting 5 min prior to the end of
ischaemia and continued for 10 min into reperfusion (n=8). The
protocol is described in Fig. 4A.
2.4. Statistical analysis
Data were expressed as meansQS.E.M. and analysed using one-
way ANOVA and Fisher’s protected least signi¢cant di¡erence test
for multiple comparisons. Values were considered signi¢cantly di¡er-
ent when P6 0.05.
3. Results
3.1. p53 and Mdm2 levels in sham and preconditioned hearts
Western blot analysis and densitometric evaluation showed
that there were no signi¢cant di¡erences between the levels of
p53 in either sham or preconditioned hearts (Fig. 1B). How-
ever, there was a signi¢cant increase in phosphorylated Mdm2
in the preconditioned hearts (1308Q 140 in preconditioned vs
475Q 70 in sham, P6 0.006, relative densitometry). In the
presence of wortmannin, the PI3K inhibitor, this increase
in phosphorylated Mdm2 was abrogated (1308Q 140 in pre-
conditioned vs 400Q 60 in preconditioned+wortmannin,
P6 0.006) (Fig. 1C). There were no signi¢cant di¡erences in
total Mdm2 between these groups.
3.2. p53 bound to phospho-Mdm2 in sham and preconditioned
hearts
The immunoprecipitation assay data (Fig. 2A) revealed that
a signi¢cant proportion of the p53 in the preconditioned
hearts was already inactivated and targeted for ubiquitination,
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being conjugated with the phosphorylated Mdm2 (73Q 9 in
sham vs 325Q 100 in preconditioned hearts P6 0.003). These
data may explain the slight di¡erence, although not signi¢-
cant, in the p53 levels between groups, noticeable from Fig.
1B. This di¡erence may be an indication that the degradation
of p53 has already started in preconditioned hearts. No un-
speci¢c binding of phosphorylated proteins on the agarose
beads in the absence of p53 was observed (Fig. 2B).
3.3. p53 level in control and preconditioned hearts which
underwent ischaemia/reperfusion injury
Interestingly the level of total p53 at 15 min reperfusion
after an ischaemic insult is signi¢cantly lower in precondi-
tioned hearts which may indicate its degradation after binding
with phospho-Mdm2 (relative densitometry was 2161Q 450 in
control vs 1166Q 269 in pi¢thrin K group, P6 0.05) (Fig. 3B).
3.4. Infarction data
To assess the role played by p53 in ischaemia/reperfusion
injury we investigated whether the reduction in its active level
prior to ischaemia or at reperfusion would be bene¢cial to the
heart. For this purpose we used a p53 inhibitor (pi¢thrin K, 10
WM), which was administered for 15 min prior to ischaemia or
5 min at the end of ischaemia and 10 min into reperfusion.
The results are expressed as percentage of infarct developed in
the risk zone (I/R%). We noticed a signi¢cant decrease of
infarction in the pre-treated hearts in comparison with the
controls (I/R% of 50.2Q 5 in controls vs 28.2 Q 3 in pi¢thrin
K pre-treated hearts, P6 0.01) (Fig. 4B). Interestingly, admin-
istration of pi¢thrin K at reperfusion was also found to be
associated with a degree of protection (I/R%=37.5Q 2,
P6 0.05). The protection induced by p53 inhibition is much
smaller than the reduction in infarction observed in the pre-
conditioned hearts (I/R%=18.4Q .2) which is not surprising
Fig. 1. Western blotting analysis of p53 and phospho-Mdm2
(P-Mdm2) in sham and preconditioned hearts. A: The experimental
protocol. B: p53 level in sham (SH) and preconditioned (IP) hearts.
C: P-Mdm2 in SH and IP hearts, with or without wortmannin.
Small dark squares= preconditioning ischaemia (5 min); *P6 0.006
vs SH, **P6 0.006 vs IP.
Fig. 2. Immunoprecipitation results concerning p53-phospho-Mdm2 (P-Mdm2) binding following the preconditioning protocol. A: P-Mdm2
bound to p53 in sham (SH) and preconditioned (IP) hearts; *P6 0.01. B: IP hearts were incubated with agarose beads with or without p53
antibody to check the unspeci¢c ligation of phosphorylated proteins, then Western blotting was performed to measure P-Mdm2. It can be seen
that there is no band for P-Mdm2 in the hearts, which were not treated with p53.
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as preconditioning is a multifactorial mechanism activating
numerous survival pathways.
4. Discussions
The mechanisms implicated in ischaemic preconditioning
protection are complex and not fully elucidated. It has re-
cently been demonstrated that the PI3K-Akt pathway, which
is considered the main survival pathway of the cell, plays a
crucial role in ischaemic preconditioning. Inactivating this
pathway using either wortmannin or LY294002 has been
shown to abolish ischaemic preconditioning [18^20]. However,
as yet there are not enough data regarding the possible sub-
strates immediately downstream of Akt, which may be re-
sponsible for this protection. From the multitude of possible
targets which can be phosphorylated by Akt and also linked
to preconditioning, only the protective role achieved by Bad
and GSK [19] phosphorylation upon the ischaemia/reperfu-
sion injury has been demonstrated.
In this study we investigated the hypothesis that one of the
mechanisms implicated in ischaemic preconditioning protec-
tion is the downregulation of p53 via activation of the
PI3K-Akt prosurvival pathway.
The implication of p53 in cell death is well documented. In
normal cells this tumour suppressor is present in an active
form and is maintained at low level. However, after an insult
which induces DNA damage, p53 is rapidly activated by phos-
phorylation at di¡erent sites, which makes it stable and pre-
vents its association with Mdm2. In this state p53 induces cell
death either directly by activating mitochondrial proapoptotic
pathways [9,10] and/or by acting as a transcription factor for
proapoptotic genes [7,8].
Mdm2 is the most important ubiquitin ligase for p53. Its
role is to maintain p53 at low levels by binding to it ^ which
means that the transcription factor cannot be activated in this
state ^ and targeting it for proteosomal degradation. It has
recently been demonstrated that Akt phosphorylates Mdm2 at
Ser166 [15,16] and Ser186 [5] and it is believed that this phos-
phorylation regulates the a⁄nity of Mdm2 for p53. Therefore
it has been suggested that Mdm2 represents a link between
two opposite processes, namely survival via the PI3K-Akt
pathway and cell death via p53 [4]. The phosphorylation of
Mdm2 is followed by its translocation to the nucleus [21]. In
the nucleus phospho-Mdm2 forms complexes with p53, block-
ing its capacity to be activated. The complexes shuttle back to
the cytoplasm where p53 is then targeted for degradation [22].
There is a large body of evidence implicating p53 in cell
death associated with myocardial ischaemia/reperfusion in-
jury. In a swine model it has been shown that following an
ischaemia/reperfusion injury p53 level is increased even 72 h
later, which demonstrates a continuous activation of death
mechanisms [11]. On the contrary inhibiting p53 with a spe-
ci¢c inhibitor (pi¢thrin K) proved to be protective against
ischaemia/reperfusion-induced cell death not only in brain
Fig. 3. Experimental protocol and Western blotting results measuring p53 levels in control and preconditioned hearts, which underwent 35 min
lethal ischaemia and 15 min reperfusion. A: The experimental protocol. B: p53 levels illustrated as Western blotting images (above) and densi-
tometric analysis (below); small dark squares=preconditioning ischaemia (5 min); black rectangle= lethal ischaemia (*P6 0.05).
Fig. 4. Experimental protocol and infarct data demonstrating the in-
£uence of p53 inhibition upon infarction when administered prior
to ischaemia or at reperfusion. Comparison with the protection
a¡orded by ischaemic preconditioning. A: Experimental protocol.
A1: Preconditioning protocol. A2: Control protocol without/with
the addition of pi¢thrin K either prior to ischaemia or at reperfu-
sion. Clear delineated rectangles represent ischaemic periods, black
rectangles represent the timing and length of pi¢thrin K administra-
tion. B: Infarction developed in the risk zone in control and pre-
conditioned hearts and in hearts treated with 10 WM pi¢thrin K be-
fore ischaemia or at reperfusion (*P6 0.01 vs control).
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[13] but also in heart, as we demonstrated for the ¢rst time in
the present study.
This protection is present when the inhibitor is administered
either before (as a preconditioning mimetic) or at reperfusion
(independent of preconditioning). The results are not surpris-
ing as p53 is activated by stresses related either to ischaemia
(hypoxia) or to reperfusion injury (free radical release, DNA
damage). We think that the phosphorylation of Mdm2 due to
preconditioning followed by its binding to p53 has the initial
e¡ect of blocking the capacity of p53 to be activated when the
above stresses take place, without changing the actual cellular
level of the transcription factor. Subsequently ubiquitination
will determine a decrease in the p53 level at reperfusion as
others [12] and we have reported. This protection is mimicked
by pi¢thrin K administered prior to ischaemia and at reperfu-
sion. The achieved protection is manifested against acute, im-
mediate, non-transcriptional proapoptotic e¡ects of activated
p53 [9,10] but more research in the ¢eld is needed to provide a
clear answer.
It is also necessary to underline that preconditioning is a
complex phenomenon in which protection is achieved by a
number of mechanisms, amongst which there is the process
of the reduction in p53 availability. Therefore pi¢thrin K may
well induce a less marked protection compared to ischaemic
preconditioning when administered prior to ischaemia. In ad-
dition it must never be forgotten that reperfusion, although a
prerequisite to tissue salvage, is also associated with a para-
doxical injury which is presumably small but biologically sig-
ni¢cant. Therefore any agent which will reduce infarction
when given at reperfusion will never reach the level of pro-
tection achieved by preconditioning.
Our data indicate that ischaemic preconditioning plays a
role in activating Mdm2. Indeed there is a signi¢cant increase
in phospho-Mdm2 (Ser166) in hearts undergoing the precon-
ditioning protocol in comparison with sham hearts. Further-
more we showed that formation of Mdm2^p53 complexes
occurs prior to the sustained ischaemia. In this state p53 can-
not be activated and it is tagged for ubiquitination. This e¡ect
will o¡er a greater chance of survival to the myocardium
undergoing an ischaemia/reperfusion insult. Interestingly,
after 15 min of reperfusion following a lethal ischaemic injury,
the level of p53 is signi¢cantly smaller in preconditioned
hearts compared to control ones. At present we do not
know if this di¡erence is due to the initial Mdm2 phosphor-
ylation or is a consequence of the reactivation of PI3K-Akt at
reperfusion followed by a subsequent phosphorylation of
Mdm2.
In conclusion, we have demonstrated for the ¢rst time that
ischaemic preconditioning is associated with a reduction in the
availability of p53 to be activated, an e¡ect that is due to its
binding to phospho-Mdm2. This e¡ect is a consequence of an
increase in Mdm2 phosphorylation in preconditioned hearts,
probably via the PI3K-Akt pathway. This may represent one
of the mechanisms through which ischaemic preconditioning
protection is achieved.
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